JP2016196450A - Agent for inhibiting rise in blood glucose, comprising indigestible glucan, and use therefor - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a novel agent for inhibiting a rise in blood glucose which can be produced by a convenient and inexpensive production method.SOLUTION: The present invention provides an agent for inhibiting a rise in blood glucose that comprises indigestible glucan comprising a sugar condensate obtained by thermally condensing a starch decomposition product with DE 70-100 or the indigestible glucan processed product; and pharmaceuticals, quasi drugs, food and drink and feed, comprising the agent for inhibiting a rise in blood glucose.SELECTED DRAWING: Figure 5

Description

  The present invention relates to a blood sugar elevation inhibitor comprising an indigestible glucan as an active ingredient and use thereof.

In recent years, an increase in type 2 diabetes caused by lifestyle habits such as diabetes, especially eating too much, drinking too much and lack of exercise has become a major social problem. According to the results of the 2007 National Nutrition and Health Survey by the Ministry of Health, Labor and Welfare, there are 8.9 million people who are strongly suspected of having diabetes and 13.2 million people who cannot deny the possibility of diabetes in Japan. It is estimated that there are over 20 million people suspected of having diabetes. Diabetes is a very dangerous disease that, if left unattended, is accompanied by serious complications such as diabetic neuropathy, diabetic retinopathy, and diabetic nephropathy.

  So far, various compounds or compositions having an inhibitory effect on the increase in blood glucose for the purpose of treatment / prevention of diabetes have been proposed. For example, tea polyphenol (Patent Document 1), acidic heteropolysaccharide isolated from gold ears ( Patent document 2), heat-treated gum arabic (patent document 3), acid hydrolyzate of roasted dextrin (patent document 4), α-glucan having a special multi-branched structure (patent document 5), derived from germinated brown rice bran Sterol glycosides (Patent Document 6), xanthan gum and water-soluble calcium salt / citrate (Patent Document 7), extracts of Pinus fir plants (Patent Document 8), etc. It has been reported that it has a function (patent documents 1 to 8). However, each material has problems in terms of supply stability and manufacturing cost, such as extraction and purification from specific raw materials, processing, and the need for special enzymes for production. It was. Furthermore, the development of a new material has been desired also in the sense of expanding the options for blood sugar elevation inhibitors.

  On the other hand, Patent Document 9 discloses a method for producing a sugar condensate (water-soluble dietary fiber) characterized by heating raw material carbohydrates using activated carbon as a catalyst. According to this production method, a new water-soluble dietary fiber material is produced by a simple and inexpensive production method by heat-condensing starch degradation products of DE 70 to 100. However, Patent Document 9 does not disclose any blood glucose rise inhibitory action of this water-soluble dietary fiber material.

JP 04-253918 A JP 07-238031 A International Publication No. 2004/089992 JP2007-246542 International Publication No. 2008/136331 JP2011-57597A JP 2012-126682 A JP 2014-129284 A JP 2013-76044 A

  An object of the present invention is to provide a new blood sugar elevation inhibitor.

The inventors of the present application have found that an indigestible glucan composed of a sugar condensate obtained by heat condensation of a starch degradation product of DE 70 to 100 has an inhibitory effect on blood sugar elevation in vivo. The present invention is based on this finding.
That is, the present invention is as follows.
(1) A hyperglycemic inhibitor comprising an indigestible glucan comprising a sugar condensate obtained by heat condensation of a starch degradation product of DE 70 to 100 or a processed product of the indigestible glucan.
(2) The antihyperglycemic agent according to (1), wherein the indigestible glucan comprises a sugar condensate obtained by heat condensation in the presence of activated carbon.
(3) The antihyperglycemic agent according to (1) or (2), wherein the indigestible glucan comprises a sugar condensate obtained by heat condensation at 100 to 300 ° C.
(4) A pharmaceutical, a quasi-drug, a food or drink, or a feed containing the blood sugar elevation inhibitor according to any one of (1) to (3).

  According to the present invention, the use of an indigestible glucan is advantageous in that it can provide a novel antihyperglycemic agent that can be stably supplied at low cost.

It is a figure which shows the time-dependent change of the variation | change_quantity ((DELTA) blood glucose level) of the blood glucose level for 120 minutes after ingestion before ingestion of a load meal in the indigestible glucan administration group of the confirmation test 1. It is a figure which shows the time-dependent change of the variation | change_quantity ((DELTA) insulin value) of the insulin value for 120 minutes after ingestion in the indigestible glucan administration group and non-administration group of the confirmation test 1 after ingestion of a load food. It is a figure which shows AUC ((DELTA) blood glucose level AUC) of the blood glucose level variation | change_quantity in 120 minutes after ingestion before ingestion of a load food in the indigestible glucan administration group of the confirmation test 1, and a non-administration group. It is a figure which shows the test design of the confirmation test 2. FIG. It is a figure which shows a time-dependent change of the blood glucose level for 120 minutes after ingestion in the indigestible glucan administration group and the non-administration group of the confirmation test 2 before ingestion of a load food. It is a figure which shows the time-dependent change of the insulin level for 120 minutes after ingestion in the indigestible glucan administration group and non-administration group of the confirmation test 2 before ingestion of a loaded meal. It is a figure which shows the AUC of the blood glucose level for 120 minutes after ingestion in the indigestible glucan administration group and non-administration group of the confirmation test 2 before ingestion of a load food.

  The antihyperglycemic agent according to the present invention is an antihyperglycemic agent comprising an indigestible glucan comprising a sugar condensate obtained by heat condensation of a starch degradation product of DE 70 to 100 or a treated product of the indigestible glucan. is there.

  In the present invention, “indigestible glucan” means an indigestible glucan (glucose polymer), and can be obtained as a sugar condensate obtained by subjecting a starch degradation product of DE 70 to 100 to a condensation reaction by heat treatment. it can. That is, the indigestible glucan in the present invention is a heat condensate of a starch degradation product of DE 70-100. Indigestible glucan is rich in water-soluble dietary fiber fraction.

  As a starch degradation product that is a raw material for the indigestible glucan, a starch degradation product having a DE of 70 to 100 can be used. When the DE of the starch degradation product is less than 70, the decomposition is insufficient, and thus the structure derived from starch remains in the indigestible glucan obtained and tends to be easily decomposed by the enzyme in the body and easily absorbed. This is not preferable from the viewpoint of an inhibitory effect on blood sugar elevation. Here, “DE (Dextrose Equivalent)” is an index of the degree of degradation of the starch degradation product, and is a value expressed as a percentage of the solid content with the reducing sugar in the sample as glucose. The starch degradation product preferably has a DE of 75 to 100, more preferably 80 to 100. The “degraded starch of DE 70 to 100” used in the present invention may be any starch degraded product in which DE satisfies a predetermined range, and examples thereof include maltooligosaccharides, starch syrup, powder cake, glucose and the like. There are no particular restrictions on the properties, and any of crystalline products (anhydrous glucose crystals, hydrous glucose crystals, etc.), liquid products (liquid glucose, starch syrup, etc.), and amorphous powders (powder etc.) can be used. In view of the above, it is preferable to use a liquid product. In particular, the use of glucose syrup called “hydrol” which is a by-product generated in the purification process of glucose is extremely advantageous from the viewpoints of recycling and raw material cost reduction.

  In the present invention, “heat condensation” refers to condensation of a starch decomposition product under heating conditions, and the heat condensation method is well known to those skilled in the art. The heating conditions in the heat condensation are not particularly limited as long as an indigestible glucan (sugar condensate) rich in water-soluble dietary fiber is obtained by the condensation reaction, and those skilled in the art can appropriately determine the heating conditions. It is preferable to heat the resulting indigestible glucan (sugar condensate) so that the dietary fiber content is 70% or more, for example, 100 ° C. to 300 ° C. for 1 to 180 minutes, more preferably 150 ° C. to It can manufacture by heat-processing at 250 degreeC for 1-180 minutes.

  In the present invention, “heat condensation” may be performed under non-catalytic conditions, but is preferably performed in the presence of a catalyst from the viewpoint of the reaction efficiency of the condensation reaction. The catalyst is not particularly limited as long as it catalyzes a sugar condensation reaction, but inorganic acids (hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, etc.), organic acids (citric acid, fumaric acid, tartaric acid, succinic acid, acetic acid, etc.) ), Mineral substances (diatomaceous earth, activated clay, acid clay, bentonite, kaolinite, talc, etc.) and activated carbon (steam coal, zinc chloride charcoal, sulfonated activated carbon, oxidized activated carbon, etc.) can be used. In consideration of coloring and safety of the resulting water-soluble dietary fiber material, as well as taste and odor, it is preferable to use activated carbon as a catalyst. Moreover, each said catalyst can also be used in combination of 2 or more type.

  As the indigestible glucan used in the present invention, the sugar condensate obtained by the above method may be used as it is, or various processed products of indigestible glucan may be used. Examples of the indigestible glucan-treated product include an indigestible glucan enzyme-treated product, an indigestible glucan fraction-treated product, and an indigestible glucan reduction-treated product. The indigestible glucan-treated product may be a combination of a plurality of treatments.

  In the present invention, the “indigestible glucan enzyme-treated product” can be obtained by enzymatic treatment of a sugar condensate with a saccharide-degrading enzyme. The digestible site in the indigestible glucan can be decomposed by the treatment.

  The “carbohydrase” used in the present invention is an enzyme that acts on a carbohydrate and catalyzes a hydrolysis reaction, and is not particularly limited. For example, α-amylase, β-amylase, glucoamylase (amyloglucosidase) is used. , Isoamylase, pullulanase, α-glucosidase, cyclodextrin glucanotransferase, β-glucosidase, β-galactosidase, β-mannosidase, β-fructosidase, cellobiase, gentiobiase, etc. Alternatively, a plurality of enzymes may be used in combination. Α-Amylase and glucoamylase are preferred from the action of degrading into indigestible glucan, and either of these enzymes may be allowed to act alone, but it is particularly preferred that α-amylase and glucoamylase are allowed to act together.

  In the present invention, the treatment conditions for the “enzyme treatment” are not particularly limited as long as the digestible portion of the sugar condensate is digested by the enzyme treatment, and those skilled in the art can appropriately determine the enzyme treatment conditions. However, it is preferable that the glucose content is increased by 1% or more, more preferably 2% or more by enzyme treatment, for example, 20 to 120 ° C. for 30 minutes to 48 hours, more preferably 50 to 100 ° C. For 30 minutes to 48 hours.

  In the present invention, the “indigestible glucan fraction-treated product” can be obtained by fractionating the indigestible glucan enzyme-treated product so that the fraction of disaccharide or less is 15% or less. In other words, the “digestible glucan fraction-treated product” has more than 85% of saccharides of three or more sugars. Here, “%” means mass% with respect to the solid content.

In the present invention, the “fractionation treatment” is not particularly limited as long as the fraction less than or equal to the disaccharide can be reduced to 15% or less, and the separation method can use means well known to those skilled in the art. .
The fractionation treatment uses, for example, carbohydrate purification methods well known to those skilled in the art, such as membrane separation, gel filtration chromatography, carbon-celite column chromatography, strong acid cation exchange column chromatography, ethanol precipitation, and solvent precipitation. can do. The fractionation treatment is preferably performed so that the fraction of disaccharides or less is 10% or less, and particularly preferably 5% or less.

  In the present invention, the “reduced product of indigestible glucan” can be obtained by reducing the indigestible glucan. In the present invention, “reduction treatment” refers to treatment for reducing the aldehyde group of the glucosyl group at the reducing end of a sugar to a hydroxyl group. The reduction treatment method is well known to those skilled in the art, and examples thereof include a method using a hydride reducing agent, a method using a metal in a protic solvent, an electrolytic reduction method, and a catalytic hydrogenation reaction method. In the present invention, when preparing a small amount of sugar alcohol, the method using a hydride reducing agent is convenient and convenient without requiring a special device, while on the other hand, when carried out industrially on a large scale, A method using a catalytic hydrogenation reaction is preferable because it is economical and has few by-products. The “catalytic hydrogenation reaction” is a reaction in which hydrogen is added to a double bond portion of an unsaturated organic compound in the presence of a catalyst, and is generally also referred to as a hydrogenation reaction.

  The “reduction treatment” in the present invention will be specifically described. Indigestible glucan is dissolved in water, an appropriate amount of Raney nickel catalyst is added thereto, hydrogen gas is added, and reduction is performed under high temperature conditions. Next, decolorization and deionization treatment can be performed to obtain an indigestible glucan reduction treatment product.

  The blood sugar elevation inhibitor according to the present invention can be obtained by a production method in which the starch degradation product of DE 70 to 100 is subjected to a condensation reaction by heat treatment using the above-described method or the like. In the present invention, the “hyperglycemic inhibitor” means a preparation that suppresses an increase in blood glucose level accompanying digestion and absorption of carbohydrates during and after intake of a food containing carbohydrates. The blood sugar elevation inhibitor of the present invention can be used for the prevention and treatment of diabetes, particularly type 2 diabetes. Furthermore, it can be used for the prevention and treatment of diseases such as diabetic complications, lifestyle-related diseases, metabolic syndrome (visceral fat syndrome), and arteriosclerosis.

  The blood sugar elevation inhibitor according to the present invention only needs to contain indigestible glucan, and may be indigestible glucan alone or mixed with other components. For example, it may be a mixture with a known blood sugar elevation inhibitor such as tea polyphenol, heat-treated gum arabic, or roasted dextrin acid hydrolyzate or other substances having pharmacological action.

  The blood sugar elevation inhibitor according to the present invention can be formulated by adding a pharmaceutically acceptable base material or carrier to an indigestible glucan that is an active ingredient, if necessary. The antihyperglycemic agent according to the present invention is, for example, a preparation to be administered orally, and can be provided in the form of tablets, granules, powders, solutions, powders, granules, capsules and the like. Such a formulation can be usually produced according to a method used for producing a medicine. According to the present invention, the antihyperglycemic agent according to the present invention can be used by being contained in a pharmaceutical or a quasi-drug.

  The blood sugar elevation inhibitor of the present invention can also be provided by being contained in food or drink. That is, it is also possible to provide a food / beverage product for suppressing an increase in blood glucose containing an indigestible glucan or a processed product thereof. There are no particular restrictions on the types of foods and drinks to be added, such as foods and drinks to be eaten on a daily basis, health foods (food for specified health use, nutritional functional foods, nutritional supplements, etc.), functional foods, foods for the sick, etc. Can be provided. Examples of the form include foods and drinks, tablets, liquids, capsules (soft capsules, hard capsules), powders, granules, sticks, jelly, and the like. Such foods and drinks can usually be produced according to the methods used for producing foods. The “special health food” refers to a food that may be subject to some legal restrictions from the viewpoint of health when the function or the like is displayed to manufacture or sell the food.

  Furthermore, the blood sugar elevation inhibitor of the present invention can be used by being contained in feeds for breeding / cultured animals (livestock, poultry, fish, etc.) and pets / competent animals.

  The usage-amount of the blood sugar elevation inhibitor by this invention is not restrict | limited in particular, It can set suitably. For example, the indigestible glucan or the processed product thereof can be set so that the amount of dietary fiber is ingested 1 to 30 g, preferably 1 to 10 g per day.

  ADVANTAGE OF THE INVENTION According to this invention, the pharmaceutical which contains the indigestible glucan which consists of a sugar condensate obtained by heat-condensing the starch degradation product of DE70-100, or this indigestible glucan processed product as a blood glucose rise inhibitor as a blood sugar rise inhibitor Foreign goods, food and drink, and feed are provided. The content of the indigestible glucan or the processed material of the indigestible glucan is not particularly limited, and the content varies depending on the product form. For example, when it is contained in a pharmaceutical product, it is 1 to 20% by mass. When it is contained, it can be 1 to 20% by mass, when it is contained in food or drink, it can be 0.5 to 10% by mass, and when it is contained in feed, it can be 1 to 20% by mass.

The present invention will be specifically described based on the following examples, but the present invention is not limited to these examples.
Example: Confirmation test of blood glucose elevation inhibitory effect of indigestible glucan

[Confirmation test 1]

Table 1 shows the formulation of the test food test food.

  Table 2 shows the nutritional components of the test food.

  As an indigestible glucan, a powder obtained by decolorizing, purifying, concentrating, fractionating resin, and drying Fit Fiber # 80 (manufactured by Nippon Shokuhin Kako Co., Ltd.) with α-amylase and glucoamylase, used. Fit fiber # 80 is a sugar condensate obtained by heat condensing a starch decomposition product of DE87 (measured by the Lane Einon method) using activated carbon as a catalyst according to the method described in JP2013-76044A.

  As the maltodextrin, Paindex # 2 (manufactured by Matsutani Chemical Industry Co., Ltd.) was used. In addition, the color tone of maltodextrin was adjusted using a coloring agent (caramel) so that it might become the same color as indigestible glucan.

Selection criteria for subjects The subjects were those who met the following selection criteria.
1) Males and females 20 years old and older and under 65 years old 2) As a result of the screening test, the responsible investigator has diabetics (1: Fasting blood glucose level 110 mg / dL or more and 125 mg / dL or less, 2: Glucose tolerance test (Traillan G75g) Load) 2 hours value 140mg / dL or more and 199mg / dL or less, 3: Applicable blood glucose level 140mg / dL or more and 199mg / dL or less) 3) Those who are not alcohol heavy drinkers (screening test) (Person who can ban alcohol from 2 days before each load test)
4) A person who has received sufficient explanation about the purpose and content of the exam, has the ability to consent, has voluntarily understood and volunteered to participate, and has agreed to participate in the exam in writing.

Study design In the study, subjects were first observed for 2 weeks prior. After that, the load test was performed after 12 hours or more from the ingestion of dinner the night before the load test to the start of the load test. The number of subjects was 23 in the non-administration group and 23 in the administration group.

As for the test food, one package dissolved in 100 ml of water was consumed within 10 minutes simultaneously with the load meal (commercial rice ball (300 g of cooked rice)) and 200 ml of water, and precipitation occurred after ingestion of the test food. Then I poured water again and ingested everything.

Inspection and investigation Each item was measured in the load test, and the effectiveness was confirmed by comparing the inspection values.
1. 1. Change in blood glucose level over time 2. Change in insulin level over time AUC of blood glucose level (area under the blood concentration curve)

Analysis on effectiveness The changes in blood glucose level and insulin level with time were compared by the following procedure.
1) Subtract the numerical value before ingesting the loaded food from the test value to calculate the amount of change (Δ blood glucose level and Δ insulin value), and analyze the basic statistics (average value, standard error).
2) The values of the non-administered group and the administered group are compared by Dunnett test before and after loading, 30, 60, 90, and 120 minutes after ingestion.

The AUC of blood glucose level was compared by the following procedure.
1) From the blood glucose level change amount (Δ blood glucose level) calculated in the above procedure based on the test value, the AUC of the blood glucose level change amount (Δ blood glucose level AUC) is calculated by the trapezoidal method (trapezoidal method).
2) Calculate basic statistics (mean value, standard error).
3) With respect to the Δ blood glucose level AUC, the values of the non-administered group and the administered group are compared by the Dunnett test.

Test Results Analysis was performed on changes in blood glucose level change over time and changes in insulin level change over time, and the change amounts in the non-administered group and the administration group are shown in FIGS. 1 and 2, respectively.

The blood glucose level change amount (Δ blood glucose level) was significantly lower than that of the non-administered group at 60 minutes after ingestion (Dunnett test: p = 0.003). There was no significant difference in the amount of change in insulin value (Δ insulin value), but it showed a low value at 60, 90, and 120 minutes after ingestion.

The AUC of the blood glucose level change amount (Δ blood glucose level AUC) was analyzed, and the Δ blood glucose level AUC of the non-administered group and the administered group are shown in FIG.

In the Δ blood glucose level AUC, the administration group showed a significantly lower value compared to the non-administration group (Dunnett test: p = 0.040).

  According to this test, the indigestible glucan in the present invention showed significantly lower values in the administration group compared to the non-administration group for the Δ blood glucose level and the Δ blood glucose level AUC. There was no significant difference in Δinsulin level, but low values were confirmed at 60, 90, and 120 minutes after ingestion. It is confirmed from the subject's records that other conditions do not affect the determination of effectiveness.

[Confirmation test 2]

Table 3 shows the formulations of the test food test food.

  Table 4 shows the nutritional components of the test food.

  As an indigestible glucan, a powder obtained by decolorizing, purifying, concentrating, fractionating resin, and drying Fit Fiber # 80 (manufactured by Nippon Shokuhin Kako Co., Ltd.) with α-amylase and glucoamylase, used. Fit fiber # 80 is a sugar condensate obtained by heat condensing a starch decomposition product of DE87 (measured by the Lane Einon method) using activated carbon as a catalyst according to the method described in JP2013-76044A.

  As the maltodextrin, Paindex # 2 (manufactured by Matsutani Chemical Industry Co., Ltd.) was used. In addition, the color tone of maltodextrin was adjusted using a coloring agent (caramel) so that it might become the same color as indigestible glucan.

Selection criteria for subjects The subjects were those who met the following selection criteria.
1) Males and females 20 years old and older and 64 years old and younger 2) Those who have a fasting blood glucose level of 110 mg / dL or more and 125 mg / dL or less as a result of a screening test, or after ingestion of a loaded food in a preliminary test Those whose blood glucose level for 30 minutes falls between 140 mg / dL and 199 mg / dL.
3) Those who do not regularly use foods (including foods for specified health use) that contain a lot of dietary fiber materials (indigestible dextrin, polydextrose, indigestible glucan, etc.) 4) May affect blood glucose metabolism Those who do not take medicines or use special health foods or functionally labeled foods 4) Receive sufficient explanation about the purpose and content of the study, have the ability to consent, and volunteer to participate voluntarily with understanding Those who have agreed to participate in the examination in writing

Study design The study was a randomized, double-blind, crossover study with a single dose of each of the non-dose group test food and the dose group test food. First, meals were recorded for subjects from 3 days before the pre-examination, and as a pre-examination, lifestyle questionnaire, physical condition confirmation, measurement, fasting clinical examination (blood, urine), dietary load examination (taken with water) were conducted. . Ingestion phase I test was conducted for more than 4 weeks after the pre-inspection. Ingestion stage I testing test was to ingest the loaded food on an empty stomach early in the morning after fasting for 10 hours or more. After ingesting the loaded food, blood was collected over time. The intake phase II test was conducted after a period of one week or more from the intake phase I test. The number of subjects was 53. The detailed test design is shown in FIG.

In addition, the test food which melt | dissolved 1 sachet in about 280 ml of water was ingested without remaining within 10 minutes simultaneously with a load meal (300 g of commercially available cooked rice and 210 g of oyakodon).

Inspection and investigation Each item was measured in the test, and the effectiveness was confirmed by comparing the inspection values.
1) Primary endpoint: Area under the blood glucose concentration time curve after ingestion of loaded food (blood glucose AUC)
2) Secondary evaluation items: fasting blood glucose level, 30 minutes, 60 minutes, 90 minutes, 120 minutes after intake of loaded food, fasting insulin level, 30 minutes after intake of loaded food, 60 minutes, 90 minutes, 120 Insulin value in minutes

Analysis on effectiveness For blood glucose AUC, after analyzing the order effect and the timing effect, and confirming that the crossover design was appropriate, repeated analysis of variance using a general linear model was used for each evaluation item. The food effect was evaluated.

The changes in blood glucose level over time and insulin level over time were compared by the following procedure.
1) Basic statistics (average value, standard error) are calculated from test values for fasting, 30 minutes, 60 minutes, 90 minutes, and 120 minutes after ingestion of loaded food in the administration group and the non-administration group.
2) Evaluate the food effect using repeated measures analysis of variance with a general linear model of the values of the administration group and the non-administration group for 30, 60, 90 and 120 minutes after ingestion of the loaded food.

The AUC of blood glucose level was compared by the following procedure.
1) Basic statistics (average value, standard error) are calculated from test values for fasting, 30 minutes, 60 minutes, 90 minutes, and 120 minutes after ingestion of loaded food in the administration group and the non-administration group.
2) Based on the test value, the blood glucose AUC is calculated by the trapezoidal method (trapezoidal method) from the blood glucose level calculated in the above procedure.
3) For blood glucose AUC, evaluate the food effect using repeated measures analysis of variance with a general linear model for the values of the administration group and the non-administration group.

Test results A time effect (p = 0.039) using blood glucose AUC was observed, but no order effect (p = 0.393) was observed. Therefore, it was judged that the results of this study can be properly evaluated based on the crossover design.

The time-dependent change in blood glucose level and the time-dependent change in insulin level were analyzed for the administration group and the non-administration group, and are shown in FIGS. 4 and 5, respectively.

As a result of analysis of variance at the blood glucose level 60 minutes after ingestion of the loaded food, a significant difference (p = 0.043) was observed between the administration group and the non-administration group. As a result of analysis of variance at the blood glucose level 90 minutes after ingestion of the loaded food, a significant difference (p = 0.044) was observed between the administration group and the non-administration group.

The AUC of the blood glucose level in the administration group and the non-administration group was analyzed and is shown in FIG.

As a result of analysis of variance in blood glucose AUC, a significant difference (p = 0.042) was observed between the administration group and the non-administration group.

  In this test, the ingestion of indigestible glucan in the present invention showed a significant increase inhibitory effect in the blood glucose AUC as the main evaluation item compared with the non-administration group, and 60 minutes after the ingestion of the load food as the secondary evaluation item. Even at a blood glucose level of 90 minutes, a significant increase inhibitory effect was observed compared to the non-administered group. It is confirmed from the subject's records that other conditions do not affect the determination of effectiveness. There was no problem with the safety of the test food under the test conditions.

  From the above, it was shown that the indigestible glucan according to the present invention has a blood glucose increase inhibitory effect and is useful as a blood glucose increase inhibitor.

Claims (4)

A hyperglycemic inhibitor comprising an indigestible glucan composed of a sugar condensate obtained by heat condensation of a starch degradation product of DE 70 to 100 or a processed product of the indigestible glucan.   The blood sugar elevation inhibitor according to claim 1, wherein the indigestible glucan comprises a sugar condensate obtained by heat condensation in the presence of activated carbon.   The blood sugar elevation inhibitor according to claim 1 or 2, wherein the indigestible glucan comprises a sugar condensate obtained by heat condensation at 100 to 300 ° C.   A pharmaceutical, a quasi-drug, a food or drink, or a feed comprising the blood sugar elevation inhibitor according to any one of claims 1 to 3.

Images